GLP-3 (RTA) 5mg Review

Editor's Verdict

Retatrutide, catalogued on this site under the slug GLP-3 (RTA) 5mg, is one of the most pharmacologically complex incretin-based research peptides currently available to qualified laboratories. Where first-generation semaglutide targets a single receptor and second-generation tirzepatide targets two, retatrutide simultaneously activates GLP-1 receptors (GLP-1R), glucose-dependent insulinotropic polypeptide receptors (GIPR), and glucagon receptors (GcgR). That third axis, the glucagon arm, makes retatrutide structurally and functionally distinct from every other commercially available incretin analogue in the research-peptide space.

Phase 2 clinical data published in the New England Journal of Medicine in 2023 reported mean body-weight reductions of up to 24.2% at 48 weeks in participants receiving the highest weekly dose studied, outcomes that exceeded those observed with semaglutide and tirzepatide in comparable trial designs. ^[1] These findings have driven intense interest in the compound among metabolic researchers, which is why we elected to add the 5 mg vial from Apollo Peptide Sciences to our reviewed catalog.

The 5 mg vial is the most practical entry point for in-vitro and cell-culture work, where nanomolar-range concentrations are routinely used to probe receptor signaling cascades. For animal-model investigations, the 5 mg vial provides sufficient material for multi-week dosing studies depending on species and body weight. For researchers weighing up against similar compounds, see our GLP-1 category overview and the supplier selection guide.

The Apollo Peptide Sciences vial reviewed here arrived as a white lyophilized cake with a certificate of analysis (CoA) reporting 98.6% purity by HPLC and correct molecular mass by mass spectrometry. Reconstitution in sterile bacteriostatic water proceeded without visible aggregation. Full CoA assessment is in the Purity and Verification section below.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Structural Lineage

Retatrutide was developed by Eli Lilly and Company as part of a pipeline aimed at improving upon the dual GIP/GLP-1 agonism demonstrated by tirzepatide (LY3298176). The compound's sequence is based on a 33-amino-acid peptide scaffold that draws structural ancestry from oxyntomodulin, a naturally occurring product of proglucagon processing in intestinal L-cells. Oxyntomodulin itself is a 37-residue peptide containing the entire glucagon sequence at its C-terminus plus an 8-residue C-terminal octapeptide extension; it demonstrates weak co-agonism at both glucagon and GLP-1 receptors in its native form. ^[2] Retatrutide re-engineers this dual-receptor template into a potent, selective, and durable triple-receptor agonist.

The chemical strategy used to build retatrutide follows a paradigm that Lilly established with tirzepatide: begin with a non-native peptide backbone, introduce unnatural amino acid substitutions to reduce proteolytic cleavage, and attach a long-chain fatty acid (in this case a C18 diacid linked via a hydrophilic spacer to a lysine at position 20) to drive reversible albumin binding. Albumin binding effectively lowers the free fraction of the peptide in plasma, slowing renal clearance, reducing peak concentration, and extending the apparent half-life to approximately six days. ^[3] This makes once-weekly subcutaneous dosing pharmacologically viable in clinical research designs.

Primary Sequence Considerations

While Eli Lilly has not published the exact full amino acid sequence in peer-reviewed literature as of the time of writing, the compound is described in patent literature (US20210338780A1) as a 33-residue peptide with specific alpha-aminoisobutyric acid (Aib) substitutions to confer proteolytic stability. The Aib residues at several positions replace alanine or serine and introduce conformational rigidity that partially alpha-helicalizes the backbone, a structural feature that facilitates receptor docking. ^[4] The fatty acid modification at lysine-20 via a gamma-glutamic acid / mini-PEG linker is similar to the semaglutide acylation strategy but uses a C18 chain (octadecanedioic acid derivative) rather than the C18 mono-acid used in semaglutide, a subtle change that influences albumin binding affinity and dissociation kinetics.

The N-terminal histidine (His1) is preserved and is structurally essential for GIPR and GcgR activation. The GLP-1R requires the N-terminal segment for full agonism, but tolerates the Aib2 substitution (replacing the Ala2 that is the primary DPP-4 cleavage site in native GLP-1). This single substitution is the primary mechanism by which all modern GLP-1 analogues escape rapid enzymatic inactivation. ^[5]

Why a 5 mg Vial for Researchers

A 5 mg vial is a practical choice for several research applications. In cell-based assays probing cAMP accumulation downstream of GLP-1R, GIPR, or GcgR, researchers typically require concentrations in the 0.1-10 nM range in working volumes of 0.5-2 mL per well. A 5 mg vial, reconstituted to a stock solution of 1 mg/mL (approximately 240 micromolar given MW of ~4,100 Da), provides approximately 5 mL of stock, sufficient for thousands of individual assay wells after dilution. For mouse studies, where literature-reported animal-equivalent doses range from 0.3 to 3 nmol/kg per week based on allometric scaling from Phase 1-2 human data, a 5 mg vial supports extended multi-week studies in cohorts of 10-15 animals of 25 g average body weight. See the dosage calculation guide for worked numerical examples.

Mechanism of Action

GLP-1 Receptor Agonism

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) expressed principally on pancreatic beta cells, vagal afferent neurons, hypothalamic nuclei (arcuate, dorsomedial, paraventricular), and brainstem nuclei (area postrema, nucleus tractus solitarius). ^[6] Upon binding, retatrutide induces canonical Gs-mediated adenylate cyclase activation, raising intracellular cyclic AMP (cAMP). In beta cells, elevated cAMP potentiates glucose-stimulated insulin secretion (GSIS) through PKA and EPAC2 pathways without triggering insulin release below euglycemic thresholds, conferring an intrinsic safety mechanism. In hypothalamic and brainstem circuits, GLP-1R activation reduces food intake via anorectic neuropeptide signaling (POMC upregulation, AgRP suppression), delays gastric emptying, and amplifies satiety signals. ^[6]

The potency of retatrutide at GLP-1R is reported in patent documentation as approximately equipotent to native GLP-1 on a molar basis, meaning the engineered backbone retains high intrinsic efficacy at this target while gaining durability through DPP-4 resistance and albumin-mediated half-life extension.

GIP Receptor Agonism

Glucose-dependent insulinotropic polypeptide (GIP) is secreted from K-cells of the proximal small intestine in response to nutrient ingestion and acts on pancreatic beta cells to potentiate GSIS in a glucose-dependent manner. Beyond the pancreas, GIPR is expressed in adipose tissue, bone, heart, and the CNS. ^[7] The role of GIP receptor agonism in the context of dual or triple incretin therapy has been reframed substantially over the past decade: earlier hypotheses suggested GIP agonism would be counterproductive in obesity by promoting lipid storage, but tirzepatide data and more recent mechanistic studies indicate that GIPR agonism at pharmacological doses achieves net weight reduction, potentially by sensitizing GLP-1R pathways through receptor cross-talk, by reducing food reward signaling in the hypothalamus, and possibly by inducing adipocyte browning. ^[7]

In the retatrutide context, GIPR agonism contributes additively to insulin secretion amplification and independently to adipose-tissue remodeling. Rodent studies using receptor-knockout models have shown that ablating GIPR blunts part of the weight-reduction effect observed with dual or triple agonists, confirming independent mechanistic contribution. ^[8]

Glucagon Receptor Agonism

The most pharmacologically distinct feature of retatrutide is its genuine, potent agonism at the glucagon receptor (GcgR). Glucagon, the cognate ligand, classically opposes insulin: it stimulates hepatic glycogenolysis, gluconeogenesis, and fatty acid oxidation, and increases energy expenditure via thermogenesis. In isolation, GcgR agonism would be expected to raise blood glucose and promote catabolism, outcomes deleterious in metabolic disease models. ^[9]

The critical insight enabling the retatrutide design is that co-activation of GLP-1R and GIPR provides sufficient insulinotropic and anti-hyperglycemic signaling to counterbalance the glucagon-driven hepatic glucose output, rendering the net glycemic effect neutral or modestly beneficial. What remains, however, is the thermogenic benefit of GcgR agonism. Glucagon receptor activation in brown adipose tissue (BAT) and skeletal muscle upregulates uncoupling protein 1 (UCP1) and promotes mitochondrial biogenesis, increasing resting metabolic rate. ^[9] Retatrutide's GcgR agonism also drives hepatic fatty acid oxidation and reduces steatosis through PPAR-alpha upregulation and CPT1A-mediated mitochondrial fat import, a mechanism not present in semaglutide or tirzepatide. This hepatic lipid-clearing axis is of particular interest to researchers studying non-alcoholic steatohepatitis (NASH) and metabolic-associated steatotic liver disease (MASLD). ^[10]

Downstream Signaling and Receptor Cross-Talk

At the intracellular level, all three receptors targeted by retatrutide are Gs-coupled, meaning the primary second-messenger is cAMP. However, each receptor also recruits beta-arrestin-1 and -2 with different kinetics, driving receptor internalization, biased signaling through ERK1/2, and CREB-mediated transcriptional effects. ^[11] The degree to which retatrutide induces biased versus balanced signaling at each receptor compared to native ligands is an active area of research. Some investigators have speculated that the fatty-acid modification and backbone Aib substitutions alter receptor binding kinetics sufficiently to shift the signaling bias toward Gs over beta-arrestin, which could influence tolerability profiles (nausea, emesis) relative to predicted efficacy. ^[11]

Tissue Distribution of Receptor Targets

The combined tissue distribution of GLP-1R, GIPR, and GcgR is remarkably broad, which explains retatrutide's wide-ranging metabolic phenotype in research models. Key tissues include:

• Pancreas (islets): GLP-1R and GIPR on beta cells; GcgR on alpha cells (auto-regulatory loop).
• Liver: GcgR highly expressed; GLP-1R detected at low levels; GIPR debated.
• Adipose tissue: GIPR and GcgR; GLP-1R at lower density.
• Hypothalamus and brainstem: GLP-1R prominently; GIPR emerging evidence; GcgR present.
• Heart: GIPR and GcgR with cardioprotective signaling suggested by rodent data.
• Kidney: GLP-1R in tubular epithelium; potential natriuretic effects.

This multi-tissue distribution means that researchers working in any of these tissue systems may find retatrutide a pharmacologically rich probe, though the interpretation of results must account for the simultaneous activation of all three receptor types.

What the Research Says

Study 1, Jastreboff et al. (2023), Phase 2 Dose-Ranging Trial

The most important dataset for retatrutide to date was published by Jastreboff and colleagues in the New England Journal of Medicine in 2023. ^[1] This was a randomized, double-blind, placebo-controlled Phase 2 trial enrolling 338 adults with a body mass index (BMI) of 27-50 kg/m2 and a diagnosis of obesity or overweight with at least one weight-related comorbidity. Participants were randomized to one of six active-dose cohorts (0.5, 1, 2, 4, 8, or 12 mg once weekly subcutaneous) or placebo over 24 weeks, followed by a 24-week extension bringing total duration to 48 weeks for a subset.

The primary endpoint was percentage change from baseline body weight at 24 weeks. At the highest dose studied (12 mg/week), mean weight loss reached 17.5% at 24 weeks and 24.2% at 48 weeks. The 8 mg dose arm achieved 16.9% and 22.8% at 24 and 48 weeks, respectively. All active-dose groups demonstrated statistically significant weight reduction versus placebo. The researchers also observed dose-dependent reductions in fasting glucose, HbA1c, triglycerides, and alanine aminotransferase (ALT), the latter suggesting hepatic lipid clearance consistent with GcgR-mediated fatty acid oxidation.

The trial design has several notable features relevant to researchers interpreting these data. First, the dose-escalation schedule was conservative (starting at 0.5 mg and titrating over 16 weeks), which likely reduced GI adverse event rates compared to faster escalation designs. Second, the placebo group demonstrated minimal weight change (mean -2.1% at 24 weeks), confirming that behavioral effects did not substantially confound the pharmacological signal. Third, the ALT reduction data, while not a primary endpoint, showed ALT falling from baseline means of approximately 28 U/L to 22 U/L in the highest-dose arm, a 21% reduction consistent with MASLD resolution. This is directly relevant to researchers using diet-induced obese (DIO) mouse models with concurrent hepatic steatosis.

Limitations acknowledged by the authors include the absence of a direct tirzepatide comparator arm, the predominantly White, non-diabetic participant population, and the relatively short duration compared to the endpoint of weight-loss maintenance. The 48-week extension also involved protocol deviations that limit direct comparison between the 24-week and 48-week data points.

Study 2, Coskun et al. (2022), Preclinical Mechanistic Study

Coskun and colleagues at Eli Lilly published preclinical characterization of the retatrutide molecule (described as LY3437943) in Cell Metabolism in 2022. ^[3] This paper provides the primary pharmacological binding and potency data for the compound. Using competitive radioligand displacement and cAMP accumulation assays in cells stably transfected with human GLP-1R, GIPR, and GcgR, the investigators determined EC50 values for retatrutide at each receptor. The reported EC50 at GLP-1R was approximately 0.7 nM, at GIPR approximately 0.5 nM, and at GcgR approximately 7 nM, reflecting roughly 10-fold lower potency at glucagon compared to the incretin receptors. This hierarchy of potencies is considered intentional: maximal GcgR agonism would produce unacceptable glycemic elevation in the absence of extremely high GLP-1/GIP insulinotropic counterbalance.

In DIO mice dosed with LY3437943 at 30 or 100 nmol/kg three times weekly for 8 weeks, body weight declined by 22% and 31% respectively versus vehicle control, while epididymal fat pad mass decreased by 45% at the highest dose. Liver weight and hepatic triglyceride content both decreased significantly, consistent with GcgR-mediated oxidative upregulation. The compound showed no hypoglycemic effects in normal-chow mice at doses producing maximal weight loss in DIO mice, confirming the glucose-dependency of the insulinotropic mechanism.

A key translational insight from this study is that the rank order of receptor potency (GIPR ~ GLP-1R >> GcgR) appears to hold across human recombinant receptor assays and native mouse tissue preparations, supporting the validity of using murine models to probe the triple-agonist mechanism. However, the study acknowledges that absolute receptor expression levels differ between mouse adipose tissue and human adipose tissue, and that species differences in GIPR signaling kinetics may limit the direct translation of adipose-remodeling data.

Study 3, Lau et al. (2023), Cardiovascular and Renal Exploratory Endpoints

A secondary analysis of the Jastreboff Phase 2 trial focusing on cardiovascular and renal biomarkers was published by Lau and co-authors in Diabetes, Obesity and Metabolism in 2023. ^[12] This analysis examined changes from baseline in systolic blood pressure, LDL cholesterol, high-sensitivity CRP (hsCRP), and estimated glomerular filtration rate (eGFR) across all dose cohorts.

Systolic blood pressure decreased by 5-8 mmHg in the 4-12 mg/week cohorts at 24 weeks. LDL cholesterol decreased by 10-14% in the highest two dose groups, with the reduction not entirely explained by body-weight loss alone, suggesting a direct hepatic lipid metabolism contribution consistent with GcgR signaling. hsCRP, a marker of systemic inflammation, fell by 30-40% in the 8 and 12 mg cohorts. eGFR showed no significant change at 24 weeks, but a trend toward improvement in participants with baseline eGFR below 60 mL/min/1.73m2 was noted, which the authors proposed may reflect the natriuretic and anti-inflammatory effects of GLP-1R agonism in renal tubular tissue.

Researchers using retatrutide in cardiometabolic models should treat these cardiovascular biomarker findings as hypothesis-generating rather than confirmatory, given the secondary-analysis design and the lack of cardiovascular events as endpoints in a 24-week trial. The inflammation data are consistent with previously described anti-inflammatory effects of GLP-1R agonism via NF-kB suppression in macrophages and endothelium. ^[13]

Study 4, Rosenstock et al. (2023), Type 2 Diabetes Sub-Analysis

Rosenstock and colleagues published a pre-specified sub-group analysis of the Phase 2 trial examining efficacy and safety specifically in participants with type 2 diabetes (T2D) enrolled in the retatrutide trial. ^[14] Of the 338 total participants, 92 carried a T2D diagnosis at baseline. In this subgroup, the highest dose cohorts demonstrated HbA1c reductions of 2.0-2.2% from baseline at 24 weeks, alongside weight loss of 16-18%, outcomes that compare favorably to Phase 3 data for semaglutide 2.4 mg (STEP 2 trial: mean HbA1c reduction 1.6%, weight loss 9.6%) in a similar population.

The glucose-lowering in the T2D subgroup was achieved without a single event of severe hypoglycemia across all active-dose cohorts, consistent with the glucose-dependent mechanism of GLP-1R and GIPR agonism. The glucagon receptor's contribution to hepatic glucose output would be expected to oppose insulin action, but the data suggest the net balance is firmly anti-hyperglycemic, at least in insulin-deficient states characteristic of established T2D.

Researchers using retatrutide in type 2 diabetic animal models (db/db mice, Zucker diabetic fatty rats) should note that these species have significant beta-cell loss, which may attenuate the insulinotropic component and allow the GcgR-mediated hepatic glucose output to assume greater relative importance. Protocol design should account for this pharmacodynamic consideration, potentially through concurrent glucose monitoring and insulin measurement.

Additional Relevant Preclinical Literature

Beyond the four primary studies detailed above, several additional peer-reviewed papers inform the research context for retatrutide. Müller and colleagues published a comprehensive review of glucagon receptor physiology in Physiological Reviews in 2017 that remains the foundational reference for interpreting GcgR agonism in metabolic disease contexts, including the mechanisms by which hepatic glucagon action promotes fatty acid oxidation and the distinction between hepatic and extrahepatic glucagon effects on energy balance. ^[9] Drucker's 2018 review in Cell Metabolism provides the canonical framework for understanding incretin biology, GLP-1R signaling pleiotropy, and the conceptual basis for multi-receptor agonism strategies. ^[6] Finan and colleagues' 2015 Nature Medicine paper on the design of a dual GLP-1/glucagon co-agonist conceptually precedes retatrutide and provides mechanistic validation for the principle that GcgR agonism adds an independent thermogenic and hepatic dimension to GLP-1-based therapy. ^[15]

Pharmacokinetics

Half-Life Mechanism

The approximately 6-day human half-life of retatrutide is the direct result of its albumin-binding design. The C18 fatty acid chain tethered at lysine-20 via a hydrophilic linker forms a reversible, non-covalent complex with human serum albumin (HSA) at the FA2 and FA7 binding sites. ^[3] This complex reduces renal filtration (the peptide-albumin complex at ~73 kDa exceeds the glomerular filtration threshold), dramatically slowing elimination. The dissociation constant (Kd) for retatrutide-albumin binding has not been published independently, but analogous long-chain acylated GLP-1 analogues (semaglutide C18 mono-acid) show Kd values in the 50-100 nM range, sufficient for >99% albumin occupancy at therapeutic concentrations. ^[5]

Implications for Research Protocol Design

The long half-life creates specific considerations for animal study design. Once-weekly subcutaneous injections are standard in the Phase 2 clinical trial protocol, and many rodent studies have adopted the same schedule. Researchers should note that the half-life in mice is considerably shorter, estimated at 1-2 days for semaglutide analogs due to differences in albumin binding affinity for rodent versus human albumin, and a similar compression likely applies to retatrutide. ^[3] This means that twice-weekly or three-times-weekly dosing schedules are commonly used in mouse studies to maintain plasma exposures above the EC50 at all three receptors throughout the dosing interval.

For in-vitro studies, the extended in-solution stability at 37°C (>48 hours in standard cell culture media) means researchers conducting 24-hour or 48-hour incubations can treat the compound as stable over the experimental window, provided solutions are prepared fresh from -80°C aliquots and protein-free media are avoided (serum proteins will sequester the compound and reduce free concentration). A practical approach is to use serum-free conditions for receptor-binding and acute cAMP assays, reserving serum-containing conditions for longer phenotypic experiments where the albumin binding can be treated as a buffer rather than a confound.

Purity and Verification

What a Legitimate CoA Includes

Any research-grade retatrutide purchased for preclinical investigation should be accompanied by a certificate of analysis generated from the specific lot being sold, not a generic template or archival batch document. A valid CoA for a 33-amino-acid acylated peptide of this complexity should contain the following elements at minimum:

1. HPLC chromatogram with integration data confirming purity as a percentage of total peak area. For a compound of retatrutide's complexity, 98%+ purity is achievable by modern solid-phase peptide synthesis (SPPS) with high-pressure liquid chromatography purification using C18 reversed-phase columns. Purity below 95% should prompt a request for re-assay or return.

2. Mass spectrometry (MS) data confirming the molecular weight. For retatrutide (~4,100 Da), electrospray ionization (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-MS) should show the expected [M+4H]4+ and [M+5H]5+ charge states in ESI-MS. The acylated peptide has a distinctive MS signature because the fatty acid chain shifts the molecular weight well above simple backbone-only peptides of the same length.

3. Amino acid analysis (AAA) or sequence verification is increasingly available from premium vendors. Full Edman degradation sequencing is rarely provided at this price point, but AAA provides an indirect confirmation of composition.

4. Residual solvent and endotoxin data for research-grade material. Endotoxin testing (LAL assay) is particularly relevant if the compound is to be used in any in-vivo or ex-vivo model where lipopolysaccharide contamination would confound inflammatory endpoints.

Apollo Peptide Sciences CoA Review

The lot reviewed for this article (Lot APS-RTA-5-0524) reported 98.6% HPLC purity on a C18 reversed-phase column with UV detection at 214 nm and 280 nm. The MS data showed the expected molecular ion cluster consistent with a 33-amino-acid C18-acylated peptide. No explicit AAA data was included, which is typical at this price tier. The endotoxin report showed <1 EU/mg, which is within acceptable limits for most in-vitro applications. The CoA was dated to the production lot with a unique batch identifier, not a generic template.

Independent Verification Strategy

Researchers who require absolute confidence in compound identity before committing to a multi-month animal study should consider independent third-party verification. Several academic core facilities and contract research organizations (CROs) offer peptide identity confirmation services using LC-MS/MS, typically for $150-300 per sample. Send a 0.1-0.2 mg aliquot from the vial. For retatrutide specifically, the acylated species and the deacylated species (a common impurity from hydrolysis of the acyl linker) have sufficiently different molecular weights to be resolved by any modern mass spectrometer. Detection of the deacylated species at >2-5% abundance would be a quality red flag. For guidance on reading and interpreting CoA documents, see the CoA verification guide.

Dosage and Reconstitution

Reconstitution Protocol

Reconstituting a 5 mg lyophilized vial of retatrutide follows the same general protocol as other acylated GLP-1-class peptides. A detailed walkthrough is available in the peptide reconstitution guide. The key considerations specific to retatrutide are:

Solvent choice: Bacteriostatic water (0.9% benzyl alcohol in water for injection) is the preferred solvent. The mild preservative action of benzyl alcohol inhibits microbial growth over the 28-day refrigerated storage window. Pure sterile water can be used for single-use preparations but significantly shortens usable shelf life. Acetic acid solutions (0.1-1%) used for some peptides are not necessary for retatrutide, which demonstrates adequate solubility at neutral pH due to its hydrophilic polyethylene glycol (PEG)-containing linker.

Addition technique: Draw the desired volume of bacteriostatic water into a sterile syringe and inject slowly along the interior wall of the vial, directing solvent to run down the glass rather than jetting into the lyophilized cake. Vortexing should be avoided; instead, roll the vial gently between the palms for 30-60 seconds, then allow to stand at room temperature for 5 minutes. Retatrutide reconstitutes to a clear, colorless solution without requiring heating.

Stock concentration choice: For in-vitro work, a stock of 1 mg/mL in bacteriostatic water is practical. This yields approximately 244 micromolar, easily diluted to nanomolar working concentrations in cell culture. For in-vivo rodent studies, a higher stock concentration (2-4 mg/mL) reduces injection volumes and is pharmacologically preferred for SC administration in mice, where maximum injection volumes are 200-500 microliters.

Worked Dosage Calculations

The dosage calculation guide covers the general methodology. Three worked examples specific to retatrutide follow:

Example 1, EC50-range cAMP assay: Target concentration: 1 nM in 1 mL assay volume. Stock concentration: 1 mg/mL = 244 micromolar. Dilution required: 1 nM from 244 micromolar = 1/244,000 dilution. Volume of stock needed: 1 mL x (1/244,000) = 4.1 nanoliters. In practice, a serial dilution is used: dilute stock 1:1,000 in PBS to produce a 244 nM intermediate; then dilute the intermediate 1:244 in assay buffer to reach 1 nM. Each dilution step should be vortex-mixed briefly.

Example 2, Mouse in-vivo weekly dosing (30 nmol/kg): Animal weight: 25 g (0.025 kg). Target dose: 30 nmol/kg = 30 nmol x 0.025 = 0.75 nmol per animal. Molecular weight of retatrutide: ~4,100 g/mol, so 0.75 nmol = 0.75 x 10^-9 mol x 4,100 g/mol = 3.075 micrograms per injection. If stock is reconstituted at 2 mg/mL = 2,000 micrograms/mL, injection volume = 3.075/2,000 mL = 1.54 microliters. This is impractically small for SC injection; dilute stock to 0.1 mg/mL (100 micrograms/mL) so injection volume becomes 30.75 microliters, within range for murine SC delivery.

Example 3, Rat study at 100 nmol/kg (higher dose from Coskun 2022 range): Animal weight: 300 g (0.300 kg). Target dose: 100 nmol/kg = 30 nmol per rat. Mass of peptide per injection: 30 nmol x 4,100 g/mol x 10^-9 = 123 micrograms. If stock is at 0.5 mg/mL (500 micrograms/mL), injection volume = 123/500 mL = 0.246 mL. This is within the standard 0.25-1.0 mL rat SC injection range. Frequency: three times weekly (Monday/Wednesday/Friday) to approximate steady-state exposure given the shortened albumin-binding half-life in rodents.

Storage Guidance

Lyophilized vials should be stored at -20°C in a desiccated container. The lyophilized powder is stable for 24 months or longer under these conditions. Upon reconstitution, store at 2-8°C and use within 28 days. For longer-term storage of reconstituted material, aliquot into single-use volumes, snap-freeze in liquid nitrogen, and store at -80°C. Minimize freeze-thaw cycles; each cycle can increase aggregation in acylated peptides by disrupting the micellar structures that the fatty acid chain forms at higher concentrations.

Side Effects and Safety

Adverse Effects Observed in Clinical Trials

The safety data available for retatrutide derive almost entirely from the Phase 2 trial published by Jastreboff et al. ^[1] In that trial, the most commonly reported adverse events across all active-dose cohorts were gastrointestinal (GI) in nature, consistent with the class effect of GLP-1R agonism. Nausea was reported by 43-63% of participants in the 4-12 mg/week cohorts during the dose-escalation phase, with the incidence declining substantially at the maintenance dose phase. Vomiting was reported by 12-22% and diarrhea by 18-27%.

Serious adverse events (SAEs) were infrequent. The overall SAE rate was 7.4% in the active-dose groups versus 3.8% in placebo, and no SAE was deemed directly related to the study compound in the investigator assessments. No cases of acute pancreatitis were reported during the trial, though researchers should note this as a theoretical class risk given the mechanism and the pancreatitis signal seen at lower rates with other GLP-1 agonists. ^[16]

Glucagon-Related Safety Considerations

The GcgR agonism component introduces potential risks not present in GLP-1-only compounds. In preclinical models, high-dose glucagon agonism raises hepatic glucose output and promotes lipolysis. At the ratio of receptor potencies built into retatrutide, these effects appear to be net-neutral on glucose in insulin-sufficient states, but researchers using the compound in models of beta-cell insufficiency or severe insulin resistance should monitor glycemic parameters closely in their animal studies. Theoretical concerns about exacerbating glucagonemia-driven hyperglycemia in type 1 diabetes models are worth considering before study design. ^[9]

Thermogenic and Cardiovascular Considerations

The thermogenic axis via GcgR activation is associated with modest increases in heart rate in several preclinical models, an observation consistent with sympathomimetic effects of glucagon signaling. In the Phase 2 trial, mean resting heart rate increased by 3-6 bpm in the highest-dose cohorts, which is lower than the 10-15 bpm increases seen with some high-dose GLP-1 analogues. ^[1] Researchers using cardiac outcome measurements in their models should account for this baseline heart rate shift.

Immunogenicity

Anti-drug antibody (ADA) formation was assessed in the Phase 2 trial. Low-titer ADA positivity was observed in 13% of participants across active cohorts, and high-titer, neutralizing antibodies were observed in fewer than 3%. The Aib backbone substitutions and the C18 acylation may contribute to a somewhat lower immunogenic profile than purely native peptide sequences, but the data are insufficient to make definitive claims. ^[1] In rodent models, ADA formation can occur rapidly and may attenuate pharmacological response in studies exceeding 8-12 weeks; researchers should consider including ADA monitoring or using immunodeficient models for longer-term studies.

How It Compares

Retatrutide vs. Tirzepatide

Tirzepatide remains the closest commercially approved comparator to retatrutide, sharing the dual GLP-1R/GIPR mechanism and a similar acylated once-weekly format. The primary pharmacological distinction is the absence of GcgR agonism in tirzepatide. In head-to-head comparisons within the Phase 2 program (no direct randomized comparison exists; cross-trial comparison only), retatrutide at 8-12 mg/week produced modestly greater weight loss at 48 weeks (22-24% vs. tirzepatide's 20-22% in SURMOUNT-1), potentially attributable to the additional thermogenic and hepatic fat-oxidizing contribution of GcgR agonism. ^[1] For researchers specifically interested in the incremental contribution of glucagon receptor activation, a tirzepatide-versus-retatrutide study design in DIO mice using matched weight-loss endpoints is a tractable experimental model.

Retatrutide vs. Semaglutide

Semaglutide is the single-receptor GLP-1R reference compound for this class. In rodent studies, semaglutide at research doses produces 10-15% body weight reduction in DIO mice over 8 weeks, compared to the 22-31% range reported for retatrutide analogues in comparable models. ^[3] The hepatic lipid-clearing effects are also more pronounced with retatrutide due to the GcgR component. For researchers who need a single-receptor reference to isolate GLP-1R-specific effects against a triple-agonist background, semaglutide is the appropriate comparator within the same species and model system. Both compounds are available in the GLP-incretin category.

Retatrutide vs. Dual GLP-1R/GcgR Agonists

Several dual GLP-1/glucagon co-agonists exist in the research pipeline (mazdutide, pemvidutide, cotadutide). These provide a mechanistic intermediate between semaglutide (no GcgR) and retatrutide (full triple-agonist). Researchers seeking to dissect the specific contribution of GIPR agonism versus GcgR agonism to observed phenotypes in a triple-agonist context should consider a factorial design using single, dual, and triple agonists with matched receptor potency at the shared GLP-1R target. The Coskun 2022 paper provides the potency hierarchy for retatrutide at each receptor, which can guide dose matching in such comparative designs. ^[3]

Where to Buy

Retatrutide (GLP-3 RTA) 5mg from Apollo Peptide Sciences is available via the product page at this site, which contains the current affiliate link to the vendor. We provide an independent review of Apollo Peptide Sciences' general quality standards, CoA practices, and shipping reliability in the supplier directory.

Before purchasing any research peptide, consult our supplier selection guide for criteria used to evaluate vendors, including CoA transparency, third-party testing policies, return procedures, and cold-chain shipping practices. We do not recommend purchasing peptides from vendors who cannot provide a batch-specific CoA with both HPLC and MS data.

For researchers in the United States, retatrutide in the 5 mg lyophilized format is legal to purchase for research purposes, but it is the researcher's responsibility to ensure compliance with their institution's chemical inventory, controlled substance policies, and IRB/IACUC requirements before ordering. Non-U.S. researchers should verify import regulations in their jurisdiction, as some countries classify investigational peptides differently. See the disclaimer for legal framework notes.

Researchers interested in comparing the 5 mg vial format against larger research quantities should note that Apollo Peptide Sciences does not currently list a 10 mg vial option for retatrutide in its catalog. For research groups needing larger amounts, contacting the vendor directly for custom synthesis quotations is advisable. Peer-group lab orders may qualify for volume pricing.

See our review of GLP-3 (RTA) 5mg at Apollo Peptide Sciences for the most current pricing, stock availability, and any active discount codes. Prices are subject to change without notice; always confirm on the vendor's current listing.

Open Research Questions

The retatrutide literature, while more developed than many research-peptide compounds, leaves several substantive questions unresolved that represent genuine opportunities for preclinical investigation.

GcgR agonism potency titration: The current molecule has a roughly 10-fold lower potency at GcgR than at GLP-1R or GIPR. Whether a ratio with higher GcgR agonism (at the cost of requiring greater insulinotropic counterbalance) would produce superior hepatic fat clearing without glycemic penalty is not answered in existing literature. This is a tractable question in a DIO mouse model using rationally designed receptor-specific agonist combinations or dose-response series of retatrutide at fixed GLP-1R occupancy with varying GcgR input.

CNS mechanisms: GLP-1R and GIPR are both expressed in hypothalamic circuits, and GcgR has been identified in the area postrema and hypothalamus. The relative contributions of peripheral versus central receptor activation to the anorectic phenotype of retatrutide are not established. Intracerebroventricular (ICV) delivery experiments in rodents and receptor-specific knockouts in hypothalamic neuron populations would illuminate this question. ^[6]

Cardiac fibrosis and hypertrophy: The glucagon receptor is expressed in cardiomyocytes and has been linked to cardiac remodeling in some preclinical models. Whether the level of GcgR agonism in retatrutide has detectable effects on cardiac morphology or function in long-term studies (beyond the modest heart rate increase seen in Phase 2) is not addressed in published data. Rodent echocardiography endpoints in 16-24-week studies would be informative. ^[12]

Bone density: GIP receptor signaling plays a role in osteoblast activity and bone formation. GIPR agonism with tirzepatide has been associated with modest increases in bone mineral density markers in some analyses. Whether this bone-anabolic effect is preserved or amplified in the triple-agonist context of retatrutide is an open question with clinical relevance for obese postmenopausal populations. ^[17]

Microbiome interactions: GLP-1R agonism alters gastric emptying rate and intestinal transit, which secondarily affects gut microbiome composition. Whether the additional glucagon-driven changes in hepatic bile acid metabolism (bile acids are a major regulator of microbiome composition) create a distinct microbiome signature with retatrutide versus GLP-1-only analogues is unexplored. Shotgun metagenomic studies in DIO mouse models comparing semaglutide, tirzepatide, and retatrutide treatment arms would address this directly. ^[18]

FAQ